AZNAstraZenecaSigning up patients
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Hepatocellular Carcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 1,220 (planned)
- Started
- May 6, 2025
- Main results expected
- Mar 15, 2030
- Fully finished
- Mar 15, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
To demonstrate the efficacy of Arm A relative to Arm C by assessment of OS in participants with advanced HCC
Measured over: Up to approximately 6 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06921785 · record last updated 2026-10-13 · checked 2026-11-09 15:47 UTC